s*k
3 楼
谢谢，这些里面哪家做的最好？听说这个方向是最有前途的方向
【在 J**********D 的大作中提到】
: http://www.fool.com/investing/general/2014/02/18/these-5-cancer
: http://www.fiercebiotech.com/tags/immunotherapy-0
: Here's a private company:
: HealthTell
: http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/01/bi
【在 J**********D 的大作中提到】
: http://www.fool.com/investing/general/2014/02/18/these-5-cancer
: http://www.fiercebiotech.com/tags/immunotherapy-0
: Here's a private company:
: HealthTell
: http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/01/bi
J*D
4 楼
Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
it belongs to the so-called immunotherapy.
http://www.ziopharm.com/pipeline/overview
On the surface it is very early stage with only several preclinical and
phase I drugs in the pipeline. However this one could be a very very big
deal. It might become a 100-billion dollar company like BIIB or CELG. The
story goes that the company, together with its partner, XON, intrexon, co-
owned a proprietary engineering technique called RheoSwitch, one of the most
promising cancer treatment technology is called chimeric antigen receptors(
CART), the existing technology is said to have side-effects therefore some
approach may have been abandoned, this RheoSwitch is supposed to serve as an
on-off switch to reduce the toxicity of drugs.The future might also lie in
the cooperation with other big pharmas and collecting licensing fees, etc.
Both ZIOP and XON have completed a 2ndary offering just last week and just
forged an alliance with MD Anderson - largest or 2nd largest cancer R&D
institution in the US.
About XON, Bill Miller, the legendary Legg Mason portfolio manager was on
CNBC the other day saying it might be the AAPL of the coming decade.
http://finance.yahoo.com/video/could-stock-decade-bill-miller-2
This company touts itself as would be google of biotech. If successful, it
may have effect in food, energy and consumer fields also, you can do some
research and find out more on this, I can provide you more info if
interested offline. I am not pumping the stocks here, but I myself am
intrigued.
Good luck.
it belongs to the so-called immunotherapy.
http://www.ziopharm.com/pipeline/overview
On the surface it is very early stage with only several preclinical and
phase I drugs in the pipeline. However this one could be a very very big
deal. It might become a 100-billion dollar company like BIIB or CELG. The
story goes that the company, together with its partner, XON, intrexon, co-
owned a proprietary engineering technique called RheoSwitch, one of the most
promising cancer treatment technology is called chimeric antigen receptors(
CART), the existing technology is said to have side-effects therefore some
approach may have been abandoned, this RheoSwitch is supposed to serve as an
on-off switch to reduce the toxicity of drugs.The future might also lie in
the cooperation with other big pharmas and collecting licensing fees, etc.
Both ZIOP and XON have completed a 2ndary offering just last week and just
forged an alliance with MD Anderson - largest or 2nd largest cancer R&D
institution in the US.
About XON, Bill Miller, the legendary Legg Mason portfolio manager was on
CNBC the other day saying it might be the AAPL of the coming decade.
http://finance.yahoo.com/video/could-stock-decade-bill-miller-2
This company touts itself as would be google of biotech. If successful, it
may have effect in food, energy and consumer fields also, you can do some
research and find out more on this, I can provide you more info if
interested offline. I am not pumping the stocks here, but I myself am
intrigued.
Good luck.
m*s
5 楼
nice
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
s*k
6 楼
Thx
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
b*d
7 楼
这个要请George和龙老师这些高人来把把脉。
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
J*D
8 楼
XON and ZIOP might really be gone...
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
J*D
9 楼
XON and ZIOP might really be gone...
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
J*D
10 楼
...
【在 J**********D 的大作中提到】
: XON and ZIOP might really be gone...
:
: most
: receptors(
【在 J**********D 的大作中提到】
: XON and ZIOP might really be gone...
:
: most
: receptors(
e*y
11 楼
ziop好像很牛啊。可惜没有早些看见。。。还能入吗？谢谢大牛
【在 J**********D 的大作中提到】
: ...
【在 J**********D 的大作中提到】
: ...
J*D
12 楼
The entire biotech sector has gone way up, reminds me of the dot com era,
when will it end? Not a good feeling...
This company is involved in the hot cancer treatment area - immunotherapy. A
technique called CAR-T, several other companies are BLUE,KITE and JUNO. But
this company stands above all others in that it's supposed to have a dimmer
which can control the amount of drugs taken. Say if it's too strong you can
turn it down somewhat. So it's universal. I would hold it hoping for dozens
of dollars or even >$100, but who knows, only put in the amount you are
able to afford, this company has no earnings and is still in very early
stage for several cancer drugs.(There are tons of companies out there!) The
huge jump for the past few days is probably an indication of huge
institutional buying and short squeeze. Bottom line, do your due diligence,
know what you own,what to expect and how much you can afford to lose.
(不是大牛，如果你想炒短线就问错人了）
when will it end? Not a good feeling...
This company is involved in the hot cancer treatment area - immunotherapy. A
technique called CAR-T, several other companies are BLUE,KITE and JUNO. But
this company stands above all others in that it's supposed to have a dimmer
which can control the amount of drugs taken. Say if it's too strong you can
turn it down somewhat. So it's universal. I would hold it hoping for dozens
of dollars or even >$100, but who knows, only put in the amount you are
able to afford, this company has no earnings and is still in very early
stage for several cancer drugs.(There are tons of companies out there!) The
huge jump for the past few days is probably an indication of huge
institutional buying and short squeeze. Bottom line, do your due diligence,
know what you own,what to expect and how much you can afford to lose.
(不是大牛，如果你想炒短线就问错人了）
w*k
13 楼
若干年前曾经有7500 XON 原始股摆在我面前，但是去了另外一家。。。
亏废了，有木有！
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
亏废了，有木有！
most
receptors(
【在 J**********D 的大作中提到】
: Not an expert by any measure, but this one is very hot lately, ZIOP, maybe
: it belongs to the so-called immunotherapy.
: http://www.ziopharm.com/pipeline/overview
: On the surface it is very early stage with only several preclinical and
: phase I drugs in the pipeline. However this one could be a very very big
: deal. It might become a 100-billion dollar company like BIIB or CELG. The
: story goes that the company, together with its partner, XON, intrexon, co-
: owned a proprietary engineering technique called RheoSwitch, one of the most
: promising cancer treatment technology is called chimeric antigen receptors(
: CART), the existing technology is said to have side-effects therefore some
J*D
14 楼
如果将来有一天人类能研制成功后悔药，这世界一定会很美好！；-）
【在 w**k 的大作中提到】
: 若干年前曾经有7500 XON 原始股摆在我面前，但是去了另外一家。。。
: 亏废了，有木有！
:
: most
: receptors(
【在 w**k 的大作中提到】
: 若干年前曾经有7500 XON 原始股摆在我面前，但是去了另外一家。。。
: 亏废了，有木有！
:
: most
: receptors(
w*k
15 楼
倒也不一定真后悔，XON解禁的时候好像是25左右，我想我估计会套现一半吧
当时如果去了XON，估计会因为原始股而不怎么挪窝吧
而且基本上和现在做的方向就完全不同
【在 J**********D 的大作中提到】
: 如果将来有一天人类能研制成功后悔药，这世界一定会很美好！；-）
当时如果去了XON，估计会因为原始股而不怎么挪窝吧
而且基本上和现在做的方向就完全不同
【在 J**********D 的大作中提到】
: 如果将来有一天人类能研制成功后悔药，这世界一定会很美好！；-）
相关阅读